BPC 157 prevented liver necrosis in three different injury models and outperformed bromocriptine, amantadine, and somatostatin — effective both orally and by injection.
Outperformed 3 reference drugsBPC 157 provided better liver protection than bromocriptine, amantadine, and somatostatin across all three injury models
What the researchers found
BPC 157 prevented liver necrosis and fatty changes in bile duct ligation, restraint stress, and CCl4 models. Effective orally and intraperitoneally. Outperformed bromocriptine, amantadine, and somatostatin.
Why it matters
BPC 157's liver protection across multiple injury types suggests a broad protective mechanism. Its oral effectiveness is especially important because it means the peptide could be taken as a pill.
How the study worked
Rats were subjected to bile duct + hepatic artery ligation, 48-hour restraint stress, or CCl4 administration. BPC 157 was given intragastrically or intraperitoneally. Liver tissue was examined histologically.
What this study cannot tell us
Animal study in rats. Three acute/subacute injury models may not represent chronic liver disease. Mechanism of protection not identified. No dose-response data presented in abstract.
How to read the evidence
Moderate — animal study with multiple injury models and active comparators. Strengthened by cross-model consistency, limited by lack of human data.
When this study was published
Published in 1993 (33 years ago). BPC 157 continues to be studied for its multi-organ protective properties.
The bigger picture
Liver damage from stress, toxins, and surgical complications is a major medical problem. A peptide that protects the liver across multiple injury types — and works orally — could become a significant therapeutic tool.
Questions still open
- What is BPC 157's mechanism of liver protection?
- Would these results translate to human liver disease?
Common questions
What is BPC 157?
Why is oral effectiveness important?
Read the original research
Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.
Life sciences, 53(18), PL291-6
Citation
Sikiric, P; Seiwerth, S; Grabarevic, Z; Rucman, R; Petek, M; Rotkvic, I; Turkovic, B; Jagic, V; Mildner, B; Duvnjak, M. (1993). Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.. Life sciences, 53(18), PL291-6.